注射用门冬氨酸鸟氨酸对消化道肿瘤肝转移癌化疗药物致肝损害的保护作用及不良反应

Protective Effects of L - ornithine - L - aspartate Injection on Liver Damage Induced - Chemotherapy in Patients with Digestive Cancer Liver Metastases

目的:探讨注射用门冬氨酸鸟氨酸在消化道肿瘤肝转移癌化疗中对肝脏的保护作用及不良反应。方法:将60例消化道肿瘤肝转移癌患者随机分为两组,患者均给予FOLFOX方案化疗。对照组30例:单用FOLFOX化疗;治疗组30例:FOLFOX方案化疗+注射用门冬氨酸鸟氨酸静脉滴注。所有患者在化疗前及化疗后第5天、14天检测血生化指标和血氨并观察不良反应。结果:治疗后对照组患者血清谷草转氨酶(AST)、丙氨酸转氨酶(ALT)、血清总胆红素(TBIL)及血氨水平明显升高(P<0.05),而治疗组患者血清指标和血氨水平在化疗前后无明显变化(P>0.05)。两组不良反应相似,但消化道反应治疗组Ⅲ°～Ⅳ°明显升高,与对照组相比,差异有统计学意义(P<0.05)。结论:门冬氨酸鸟氨酸在消化道肿瘤肝转移癌患者化疗过程中起到保护肝功能的作用,但增加了消化道不良反应。

Objective： To observe protective effects and adverse reaction of L - omithine - L - aspartate （OA） injection on liver damage induced - chemotherapy in patients with digestive cancer liver metastases. Methods：We assigned 60 patients, who had digestive cancer liver metastases, in random order, to receive FOLFOX chemotherapy only （the control group,n = 30） or FOLFOX Plus OA therapy （treatment group,n = 30）. And serum level of AST,ALT,COGT, TBIL and blood ammonia were detected before and after 5 and 14 days chemotherapy. The resuits were compared between the two groups. Results： As compared with before chemotherapy, serum level of AST, ALT,TBIL and blood ammonia in the control group was increased significantly （ P 〈 0.05） after chemotherapy, and these did not changed in the treatment group after chemotherapy （P 〉 0.05）. The two groups were similar with regard to adverse reaction but digestive reaction was clearer （ P 〈 0.05） in treatment group as compared with control group. Conclusions： OA plays a role in protection of liver during chemotherapy in patients with digestive cancer liver metastases, however, adverse reaction of digestion is clearer.